Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study

The Lancet Oncology

Volumn 9, Issue 3, 2008, Pages 239-246

  Schoemaker, Minouk J ^a   Swerdlow, Anthony J ^a   Higgins, Craig D ^a   Wright, Alan F ^b   Jacobs, Patricia A ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE DERIVATIVE;

ADOLESCENT; ADULT; AGE; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHROMOSOME ABERRATION; COHORT ANALYSIS; CYTOGENETICS; EYE CANCER; FEMALE; FOLLOW UP; GONADOBLASTOMA; HEREDITY; HORMONAL THERAPY; HUMAN; KAPLAN MEIER METHOD; KARYOTYPE 45,X; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGIOMA; MONOSOMY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN CANCER; TURNER SYNDROME; UNITED KINGDOM; URETHRA CANCER; UTERUS CANCER; X CHROMOSOME; Y CHROMOSOME; AGED; CLASSIFICATION; CLINICAL TRIAL; GENETICS; INCIDENCE; INFANT; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PRESCHOOL CHILD; REGISTER; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; INFANT; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK FACTORS; TURNER SYNDROME;

EID: 40749104900     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70033-0     Document Type: Article

References (35)

1. Stochholm K., Juul S., Juel K., Naeraa R., and Gravholt C. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 91 (2006) 3897-3902
2. Elsheikh M., Dunger D., Conway G., and Wass J. Turner's syndrome in adulthood. Endocr Rev 23 (2002) 120-140
3. Verp M., and Simpson J. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 25 (1987) 191-218
4. Gravholt C., Fedder J., Naeraa R., and Muller J. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab 85 (2000) 3199-3202
5. Wertelecki W., Fraumeni Jr. J., and Mulvihill J. Nongonadal neoplasia in Turner's syndrome. Cancer 26 (1970) 485-488
6. Satge D., Moore S., Stiller C., et al. Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet Cytogenet 147 (2003) 89-98
7. Clement P., and Young R. Atypical polypoid adenomyoma of the uterus associated with Turner's syndrome. A report of three cases, including a review of "estrogen-associated" endometrial neoplasms and neoplasms associated with Turner's syndrome. Int J Gynecol Pathol 6 (1987) 104-113
8. Kocova M., Basheska N., Papazovska A., Jankova R., Toncheva D., and Popovska S. Girls with Turner's syndrome with spontaneous menarche have an increased risk of endometrial carcinoma: a case report and review from the literature. Gynecol Oncol 96 (2005) 840-845
9. Price W., Clayton J., Collyer S., De Mey R., and Wilson J. Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. J Epidemiol Community Health 40 (1986) 97-102
10. Swerdlow A., Hermon C., Jacobs P., et al. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. Ann Hum Genet 65 (2001) 177-188
11. Hasle H., Olsen J., Nielsen J., Hansen J., Friedrich U., and Tommerup N. Occurrence of cancer in women with Turner syndrome. Br J Cancer 73 (1996) 1156-1159
12. Gravholt C., Juul S., Naeraa R., and Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 51 (1998) 147-158
13. WHO. International Statistical Classification of diseases and related health problems, 9th revision (1977), World Health Organization, Geneva
14. Breslow N., and Day N. Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC scientific publication, no. 82 (1987), International Agency for Research on Cancer, Lyon
15. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
16. StataCorp. Stata statistical software: release 9.0 (2006), Stata Corporation, College Station, Texas
17. Swerdlow A., dos Santos Silva I., and Doll R. Cancer incidence and mortality in England and Wales: trends and risk factors (2001), Oxford University Press, Oxford
18. Claus E., Black P., Bondy M., et al. Exogenous hormone use and meningioma risk: what do we tell our patients?. Cancer 110 (2007) 471-476
19. Gravholt C., Vestergaard P., Hermann A., Mosekilde L., Brixen K., and Christiansen J. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clin Endocrinol (Oxf) 59 (2003) 89-96
20. Bondy C., Ceniceros I., Lange E., and Bakalov V. Declining estrogen use in young women with Turner syndrome. Arch Intern Med 166 (2006) 1322
21. El Mansoury M., Barrenas M., Bryman I., et al. Chromosomal mosaicism mitigates stigmata and cardiovascular risk factors in Turner syndrome. Clin Endocrinol (Oxf) 66 (2007) 744-751
22. Bondy C. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92 (2007) 10-25
23. Sklar C. Growth hormone treatment: cancer risk. Horm Res 62 suppl 3 (2004) 30-34
24. Jostel A., Mukherjee A., Hulse P., and Shalet S. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) 62 (2005) 698-705
25. Khandwala H., McCutcheon I., Flyvbjerg A., and Friend K. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 (2000) 215-244
26. Swerdlow A. Does growth hormone therapy increase the risk of cancer?. Nat Clin Pract Endocrinol Metab 2 (2006) 530-531
27. Silverman D., Devesa S., Moore L., and Rothman N. Bladder cancer. In: Schottenfeld D., and Fraumeni Jr. J. (Eds). Cancer epidemiology and prevention (2006), Oxford University Press, New York 1101-1127
28. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
29. Brown C., and Greally J. A stain upon the silence: genes escaping X inactivation. Trends Genet 19 (2003) 432-438
30. Liao D., Du Q., Yu B., Grignon D., and Sarkar F. Novel perspective: focusing on the X chromosome in reproductive cancers. Cancer Invest 21 (2003) 641-658
31. Deprez R.L., Riegman P., van Drunen E., et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 54 (1995) 224-235
32. Knuutila S., Aalto Y., Autio K., et al. DNA copy number losses in human neoplasms. Am J Pathol 155 (1999) 683-694
33. Indsto J., Nassif N., Kefford R., and Mann G. Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma. Clin Cancer Res 9 (2003) 6476-6482
34. Cheng L., MacLennan G., Pan C., et al. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch Pathol Lab Med 128 (2004) 187-190
35. Swerdlow A., Schoemaker M., Higgins C., Wright A., and Jacobs P. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 97 (2005) 1204-1210